Trial record 1 of 34 for:    " May 23, 2012":" June 22, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Previous Study | Return to List | Next Study

An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients (POISE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Janssen Inc.
ClinicalTrials.gov Identifier:
NCT01615601
First received: June 6, 2012
Last updated: May 20, 2014
Last verified: May 2014
  Purpose

The purpose of this study is to evaluate tolerability of darunavir (PREZISTA) or etravirine (INTELENCE) in patients infected with human immunodeficiency virus type 1 (HIV-1) who are naïve to these medications and in patients who have experienced tolerability issues on their current or prior combination antiretroviral therapy (cART). The tolerability is evaluated by switching the patients from their previous or current combination antiretroviral therapy (cART) to either darunavir or etravirine.


Condition Intervention Phase
Human Immunodeficiency Virus (HIV)
Drug: darunavir (PREZISTA)
Drug: etravirine (INTELENCE)
Drug: ritonavir
Drug: Other antiretroviral medications
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: PREZISTA or INTELENCE Switch Evaluation in Virologically Suppressed Patients Naïve to Darunavir or Etravirine and Who Are Intolerant of Their Current or Prior Combination Antiretroviral Therapy Regimen: A Phase IV, Open-label, Multicentre Observational Trial

Resource links provided by NLM:


Further study details as provided by Janssen Inc.:

Primary Outcome Measures:
  • Change from Baseline in the patient's total score of the HIV Symptom Distress Module (HIV-SDM) [ Time Frame: Baseline (Day 1), Week 4, 12 and 24 ] [ Designated as safety issue: No ]
    HIV-SDM is a questionnaire consisting of 20 questions related to all the symptoms which the patient might have had during the past four weeks. For each question patient has to select appropriate answer related to the symptoms: "0 = I do not have this symptom; 1 = I have this symptom and it doesn't bother me; 2 = it bothers me a little; 3 = it bothers me; 4 = it bothers me a lot". Total score of HIV-SDM is then calculated for all the 20 items.


Secondary Outcome Measures:
  • Number of participants with Maintenance/achievement of virologic suppression at Week 24 [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]
    Virologic suppression is decrease in the number of virus in blood. Number of participants with virologic suppression (who achieved virologic suppression) as well as the Number of participants who maintained virologic suppression will be summarized.

  • Number of participants with disappearance by Week 4 of at least one bothersome symptom identified at baseline by patient on HIV-SDM [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
    The bothersome symptoms (defined as those reported as 'It bothers me a lot' or 'It bothers me') at baseline will be identified for each patient. The number of participants who report the disappearance of at least one of the bothersome symptoms (eg, reported as 'It bothers me a little', 'It does not bothers me', 'I do not have the symptom') by Week 4 will be summarized.

  • Number of participants with maintenance of disappearance by Week 12 and Week 24 of at least one bothersome symptom identified at baseline by patient on HIV-SDM [ Time Frame: Baseline, Week 12 and Week 24 ] [ Designated as safety issue: No ]
    The number of participants who report the maintenance of the disappearance of at least one of the bothersome symptoms (eg, reported as It bothers me a little, 'It does not bothers me', 'I do not have the symptom') at Week 12 and Week 24 will be summarized.

  • Number of participants with Maintenance/increase in CD4 cell count. [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]
    CD4 cells (a type of white blood cells) are circulating in blood and gives an idea of how strong the HIV positive person's immune system really is. The values of CD4 cell counts will be summarized using mean, standard deviations, minimum and maximum at baseline and Week 24. In addition, the number of participants with maintenance or increase in CD4 cell counts will be summarized.

  • Comparison of change in HIV-SDM scores between those participants who were on or off ARTs at baseline [ Time Frame: Baseline, Week 4, Week 12 and Week 24 ] [ Designated as safety issue: No ]
    On and off ARTs is patients taking HIV medications and patients not taking HIV medications. The HIV-SDM change from baseline scores will be summarized using basic statistics (mean, standard deviations, minimum and maximum) by whether the patient is on or off ART at baseline.


Enrollment: 77
Study Start Date: October 2011
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
darunavir (PREZISTA)
PREZISTA co-administered with 100 mg ritonavir as per Canadian Product Monograph. (Observational Study)
Drug: darunavir (PREZISTA)
Form = tablet, route = oral, Units = mg, number = 800 administered once daily
Other Name: darunavir (PREZISTA)
Drug: ritonavir
Form = tablet/capsule, route = oral, Units = mg, number = 100 administered once daily
Other Name: ritonavir
etravirine (INTELENCE)
INTELENCE co-administered with other antiretroviral medicinal products as per Canadian Product Monograph (Observational Study)
Drug: etravirine (INTELENCE)
Form = tablet, route = oral, Unit = mg, number = 200, administered twice daily
Other Name: etravirine (INTELENCE)
Drug: Other antiretroviral medications
Given as per Canadian Product Monograph
Other Name: Other antiretroviral medications

Detailed Description:

This is an open label (all people know the identity of the intervention.), multicenter (study conducted at multiple sites), observational study (individuals are observed for certain outcomes) of darunavir and etravirine in patients infected with HIV-1 who are naïve to these medications and who have experienced tolerability issues on their current or prior combination antiretroviral therapy (medicines used for treatment of HIV). PREZISTA is indicated for naïve HIV patients (someone who has never used HIV drugs) and treatment-experienced HIV patients and INTELENCE is indicated for treatment-experienced patients who have failed prior therapy and have HIV-1 strains resistant to multiple antiretroviral agents (HIV-1 strains are able to survive the exposure of the multiple antiretroviral agents), including Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs). In this study patients will receive either darunavir (PREZISTA) or etravirine (INTELENCE) and physician selected optimized background agents (other antiretroviral medicines), as permitted by the local formulary and supported by the current Canadian Product Monograph. 90 patients will participate in this study (75 Patients planned for the darunavir group and 15 patients planned for the etravirine group). The total duration of the study will be 24 weeks. Safety and tolerability will be evaluated at screening (14 days prior to Day 1), baseline (patient's medical status before any treatment or research is done) at Day 1, Week 4, Week 12 and Week 24. Tolerability will be evaluated using HIV Symptom Distress Module (HIV-SDM) also referred to as the HIV Symptom Index (HSI) which is a self-completed questionnaire to evaluate symptoms and measure the presence and bothersomeness of side effects commonly seen with HIV and antiretroviral treatment over the last 4 weeks (20 questions about all symptoms which the patient might have had during the past four weeks). Higher scores indicate the presence of more symptoms and/or a greater degree of distress related to the 20 symptoms. In HIV-SDM data is collected to see the benefit of switching to either darunavir or etravirine.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients infected with human immunodeficiency virus type 1 who have experienced tolerability issues on their current or prior ccombination antiretroviral therapy regimen and for whom a regimen including darunavir and/or etravirine is clinically indicated.

Criteria

Inclusion Criteria:

  • Have a documented HIV-1 infection
  • Have 1 or more significant symptoms with at least grade 2 toxicity on the Division of AIDS Toxicity "DAIDS grading scale" on current or prior combination antiretroviral therapy (cART) regimen (current or prior cART including regimens consisting of 2 Nucleoside reverse transcriptase inhibitors (NRTIs) and a third agent with the exception of darunavir or etravirine)
  • Have stable response to current cART ie, have an HIV-plasma viral load [number of virus in blood] at screening <400 copies/mL (undetectable) or last plasma viral load on prior regimen within the previous 6 months <400 copies/mL)
  • Must not have resistance to Primary HIV protease inhibitor medicines

Exclusion Criteria:

  • Has been Infected with HIV-2 - Has received previous treatment with darunavir or etravirine or non-HAART (Highly Active Antiretroviral Therapy) regimen
  • Has had prior virologic failure to 2 or more regimens or single virologic failure on prior cART
  • Has a documented resistance to darunavir and etravirine
  • Is currently using any drug contraindicated in the current Canadian Product Monograph for darunavir or etravirine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01615601

Locations
Canada
Vancouver, Canada
Sponsors and Collaborators
Janssen Inc.
Investigators
Study Director: Janssen Inc. Clinical Trial Janssen Inc.
  More Information

No publications provided

Responsible Party: Janssen Inc.
ClinicalTrials.gov Identifier: NCT01615601     History of Changes
Other Study ID Numbers: CR018595, TMC114HIV4068
Study First Received: June 6, 2012
Last Updated: May 20, 2014
Health Authority: Canada:IRB
Canada: Ethics Review Committee

Keywords provided by Janssen Inc.:
Human Immunodeficiency Virus
HIV
HIV-1
HIV type 1
HIV symptom Distress Module
HIV-SDM
HIV Symptom Index (HSI),
Darunavir
PREZISTA
Etravirine
INTELENCE
Antiretroviral therapy

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immune System Diseases
Ritonavir
Darunavir
Etravirine
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on July 31, 2014